Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1093/ckj/sfx024 http://scihub22266oqcxt.onion/10.1093/ckj/sfx024 C5466109!5466109!28616209     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Clin+Kidney+J 2017 ; 10 (3): 320-2 Nephropedia Template TP {{tp|p=28616209|t=2017. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?|pdf=|usr=}}{{28616209}} gab.com Text Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome JO: Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=28616209 #FOAvip Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS. Twit Text FOAVip Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome ????Clin Kidney J http://www.kidney.de/pget.php?&tw=1&pmid=28616209 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=28616209 #FOAvip English Wikipedia <ref>{{Cite pmid|28616209}}</ref> Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome? #MMPMID28616209 Rodriguez E; Barrios C; Soler MJ Clin Kidney J 2017[Jun]; 10 (3): 320-2 PMID28616209show ga Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS. äShould eculizumab be discontinued in patients with atypical hemolytic (epmc).pdf DeepDyve Pubget Overpricing